aTyr Pharma Inc. (NASDAQ: ATYR) will proceed with a new Phase 3 study of efzofitimod for pulmonary sarcoidosis following feedback ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE